Tumor Time‐Course Predicts Overall Survival in Non‐Small Cell Lung Cancer Patients Treated with Atezolizumab: Dependency on Follow‐Up Time

• 主要な著者: Ida Netterberg (著者), René Bruno (著者), Ya‐Chi Chen (著者), Helen Winter (著者), Chi‐Chung Li (著者), Jin Y. Jin (著者), Lena E. Friberg (著者)
• フォーマット: 図書
• 出版事項: Wiley, 2020-02-01T00:00:00Z.
• 主題: article
• オンライン･アクセス: Connect to this object online.

The large heterogeneity in response to immune checkpoint inhibitors is driving the exploration of predictive biomarkers to identify patients who will respond to such treatment. We extended our previously suggested modeling framework of atezolizumab pharmacokinetics, IL18, and tumor size (TS) dynamic...